JMJD1C

Across TCGA pan-cancer cohorts, JMJD1C RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of JMJD1C’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where JMJD1C RNA is repressed in tumor relative to normal tissue. In most cancer types JMJD1C is over-expressed in tumor, although a few such as THCA and LUSC show the opposite, repressed pattern.

THCA, LUSC, and BRCA are the cancer types where JMJD1C tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in JMJD1C RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	II,III,IV	−0.848	<.001	8	view →
LUSC	All	II,III,IV	−0.953	<.001	6	view →
BRCA	Female	All	−0.466	<.001	6	view →
KICH	Female	All	−1.280	<.001	5	view →
KIRC	All	All	+0.337	.001	3	view →
CHOL	All	All	+1.114	<.001	2	view →
UCEC	All	All	−0.854	.001	2	view →
BLCA	All	All	−0.408	.041	2	view →
HNSC	Female	III,IV	+0.784	.023	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

JMJD1C–THCA

Open the THCA breakdown →